Guyasuta Investment Advisors Inc. Has $228,000 Holdings in CVS Health Co. (NYSE:CVS)

Guyasuta Investment Advisors Inc. lessened its holdings in shares of CVS Health Co. (NYSE:CVS) by 33.8% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,891 shares of the pharmacy operator’s stock after selling 1,475 shares during the quarter. Guyasuta Investment Advisors Inc.’s holdings in CVS Health were worth $228,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Atticus Wealth Management LLC grew its position in shares of CVS Health by 149.0% in the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock valued at $29,000 after purchasing an additional 219 shares during the last quarter. Cornerstone Planning Group LLC lifted its stake in CVS Health by 111.5% during the third quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock worth $32,000 after purchasing an additional 243 shares during the last quarter. ZRC Wealth Management LLC lifted its stake in CVS Health by 400.0% during the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock worth $39,000 after purchasing an additional 400 shares during the last quarter. Coston McIsaac & Partners lifted its stake in CVS Health by 42.6% during the fourth quarter. Coston McIsaac & Partners now owns 539 shares of the pharmacy operator’s stock worth $42,000 after purchasing an additional 161 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in CVS Health during the fourth quarter worth $50,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Activity at CVS Health

In related news, EVP Prem S. Shah sold 29,473 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $76.95, for a total value of $2,267,947.35. Following the transaction, the executive vice president now owns 39,765 shares of the company’s stock, valued at approximately $3,059,916.75. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.24% of the stock is owned by insiders.

CVS Health Stock Performance

Shares of CVS opened at $67.44 on Tuesday. CVS Health Co. has a one year low of $64.41 and a one year high of $83.25. The company has a market cap of $85.01 billion, a PE ratio of 10.44, a P/E/G ratio of 0.89 and a beta of 0.52. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.86 and a quick ratio of 0.63. The stock has a 50-day moving average of $74.22 and a 200-day moving average of $73.65.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.11. CVS Health had a net margin of 2.33% and a return on equity of 15.25%. The business had revenue of $93.81 billion for the quarter, compared to analysts’ expectations of $90.58 billion. During the same quarter last year, the firm earned $1.99 EPS. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. On average, equities research analysts predict that CVS Health Co. will post 8.31 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Monday, April 22nd will be given a $0.665 dividend. The ex-dividend date is Friday, April 19th. This represents a $2.66 annualized dividend and a yield of 3.94%. CVS Health’s payout ratio is 41.18%.

Wall Street Analyst Weigh In

CVS has been the subject of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $87.00 price target on shares of CVS Health in a research note on Wednesday, April 10th. Wells Fargo & Company dropped their price target on CVS Health from $83.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 8th. Piper Sandler increased their price objective on CVS Health from $93.00 to $94.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Barclays initiated coverage on CVS Health in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $78.00 price objective for the company. Finally, Royal Bank of Canada decreased their price objective on CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a report on Thursday, February 8th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $89.44.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.